August 1st 2023.
Anupam Rasayan India Limited, one of India’s leading custom synthesis and specialty chemical players, recently announced its financial results for the quarter ended June 30, 2023. These results show that the company has achieved a 19% year-on-year growth in total revenue, a 28% year-on-year growth in EBITDA, and a 25% year-on-year growth in profit after tax.
Mr. Anand Desai, Managing Director of Anupam Rasayan, noted that the company had achieved this consistent growth despite a challenging industry backdrop. He further commented that their customised products and robust business model had helped them deliver a strong EBITDA margin of 29% in Q1 FY24.
During the quarter, Anupam Rasayan also signed a Memorandum of Understanding (MoU) with 3xper Innoventure Ltd. for the supply of new-age pharma molecules using continuous process. In addition, Letters of Intent (LOI) worth Rs 40,660 Mn were signed with Japanese and American MNCs for niche life sciences and specialty chemical molecules. These LOIs further strengthen the company’s revenue visibility for the coming years.
Overall, Mr. Desai expressed his confidence in the company’s ability to deliver robust growth in FY24 while maintaining margins, due to the strong order book they have despite the current challenging external environment.
[This article has been trending online recently and has been generated with AI. Your feed is customized.]
[Generative AI is experimental.]
